Semaglutide in Psychiatry-Opportunities and Challenges

Sri Mahavir Agarwal; Margaret Hahn

doi:10.1001/jamapsychiatry.2024.2412

Semaglutide in Psychiatry-Opportunities and Challenges

JAMA Psychiatry. 2024 Oct 1;81(10):955-956. doi: 10.1001/jamapsychiatry.2024.2412.

Authors

Sri Mahavir Agarwal^{1

2}, Margaret Hahn^{1

2}

Affiliations

¹ Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
² Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

PMID: 39167395
DOI: 10.1001/jamapsychiatry.2024.2412

No abstract available

Plain language summary

This Viewpoint discusses clinical trial results of glucagon-like peptide 1 receptor agonists for treating the weight gain and cardiovascular disease risk of psychiatric medications.

MeSH terms

Glucagon-Like Peptides* / administration & dosage
Glucagon-Like Peptides* / therapeutic use
Humans
Mental Disorders / drug therapy

Substances

semaglutide
Glucagon-Like Peptides